指南与共识血栓与止血

血友病临床试验年出血率记录与报告方法评估:ISTH SSC沟通

Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders.
指南 / 共识 · J Thromb Haemost · 2026-09-09

ISTH SSC对27项血友病干预关键III期试验进行综述,评估出血定义与年出血率报告的一致性。多数试验(67%)未纳入出血事件定义,仅63%将年出血率作为主要疗效终点,且多数试验疗效观察期短于52周。统一的出血定义、观察时长与分析方法有助于提高治疗可比性和共享决策。

要点

  • 67%的关键III期血友病试验未纳入出血事件定义。
  • 仅63%的试验将年出血率纳入主要疗效终点。
  • 多数试验的计划疗效观察时长不足52周。

核心结论

  • 当代血友病关键III期试验在出血定义、观察时长和分析方法上仍存在显著异质性。
  • 统一实施并透明报告出血定义、观察时长和分析方法可提高治疗间可比性并支持个性化共享决策。

研究设计与样本

  • ISTH SSC因子VIII、因子IX及罕见凝血障碍分委会项目,对27项血友病干预关键III期试验的主要出版物进行综述。
  • 综述范围包括长效和高持续活性凝血因子浓缩物、非因子疗法(因子VIIIa模拟物和再平衡剂)及基因治疗的关键III期试验。

主要发现

  • 27项试验中多数(67%)未纳入出血事件定义。
  • 仅17项试验(63%)将年出血率纳入主要疗效终点。
  • 74%的试验报告所有出血事件,26%仅报告所有治疗性出血事件,33%两者均报告。
  • 多数试验的计划疗效观察时长小于52周。

临床怎么用

  • 解读血友病试验疗效时需关注出血定义、观察时长和年出血率分析方法是否一致。
  • 关键试验应透明报告出血定义、观察时长和分析方法,以支持治疗间比较和共享决策。

局限性

  • 综述仅评估关键III期试验的主要出版物,未涵盖观察性研究和登记研究。
  • 原文未报告各试验出血定义的具体差异细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bleed outcome measures, such as the annual or annualized bleed rate, are key efficacy outcomes for assessing hemophilia therapies in both clinical trials and daily practice. Significant variability in bleed definitions, efficacy observation duration, and statistical methodology have previously been reported across observational studies, registries, and investigational trials. Over a decade ago, the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee published consensus definitions for joint and muscle bleeding, target joints, and response to therapy. The present Scientific and Standardization Committee project aimed to determine whether the availability of bleed definitions and awareness of the hazards of inconsistent bleed outcome measure implementation yielded increased uniformity in design and execution of contemporary hemophilia intervention pivotal trials. A review was conducted of the primary phase III publications for extended half-life and high-sustained activity clotting factor concentrates, nonfactor therapies (factor VIIIa mimetics and rebalancing agents), and gene therapies. Among the 27 trials assessed, the majority (67%) did not include a bleed event definition. Only 17 trials (63%) incorporated annualized bleed rate into their primary efficacy outcome. All bleed events were reported by 74% of trials, 26% only reported all treated bleed events, and 33% reported both. In most trials, the planned efficacy observation duration was less than 52 weeks. Implementation and transparency of uniform bleed definitions, observation duration, and analysis methodology, particularly for pivotal trials, would facilitate both comparability among therapeutics and shared decision making for personalized care. Further, consistent harmonized adoption for all investigational hemophilia trials, observational studies, and registries would enable improved outcomes comparisons and meta-analyses.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Croteau SE, Castaman G, Fijnvandraat K, et al. Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders. J Thromb Haemost. 2026. PMID: 42716225. doi:10.1016/j.jtha.2026.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。